Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review.

ABSTRACT:

Unlabelled

Blood glucose-lowering treatment options generally target insulin action or beta-cell function. In diabetes, expression of the sodium-glucose cotransporter-2 (SGLT2) genes is up-regulated and renal threshold increased, resulting in increased glucose reabsorption from glomerular filtrate, reducing urinary glucose excretion and worsening the hyperglycemic condition. The SGLT2 inhibitors (SGLT2i) are a novel class of anti-diabetic drugs that lower blood glucose levels through the suppression of renal glucose reabsorption thereby promoting renal glucose excretion. The efficacy of SGLT2i is reduced in renal impairment because the ability of glucose-lowering is directly proportional to glomerular filtration rate. On the other hand, ongoing research suggests that SGLT2i may off

SUBMITTER: Kalra S 

PROVIDER: S-EPMC5020120 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature